Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations | Zendy

Evelyn Jiagge | Zendy; Aisha Jibril | Zendy; Melissa B. Davis | Zendy; Carlos MurgaZamalloa | Zendy; Celina G. Kleer | Zendy; Kofi K. Gyan | Zendy; George Divine | Zendy; Mark J. Hoenerhoff | Zendy; Jessica Bensenhave | Zendy; Baffour Awuah | Zendy; Joseph K. Oppong | Zendy; Ernest Adjei | Zendy; Barbara Salem | Zendy; Kathy A. Toy | Zendy; Sofía D. Merajver | Zendy; Max S. Wicha | Zendy; Lisa A. Newman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations

Author(s) -

Evelyn Jiagge,

Aisha Jibril,

Melissa B. Davis,

Carlos MurgaZamalloa,

Celina G. Kleer,

Kofi K. Gyan,

George Divine,

Mark J. Hoenerhoff,

Jessica Bensenhave,

Baffour Awuah,

Joseph K. Oppong,

Ernest Adjei,

Barbara Salem,

Kathy A. Toy,

Sofía D. Merajver,

Max S. Wicha,

Lisa A. Newman

Publication year - 2018

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.18.00056

Subject(s) - androgen receptor , medicine , breast cancer , estrogen receptor , progesterone receptor , oncology , population , androgen , endocrinology , cancer , gynecology , hormone , prostate cancer , environmental health

Population-based incidence rates of breast cancers that are negative for estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2/ neu (triple-negative breast cancer [TNBC]) are higher among African American (AA) compared with white American (WA) women, and TNBC prevalence is elevated among selected populations of African patients. The extent to which TNBC risk is related to East African versus West African ancestry, and whether these associations extend to expression of other biomarkers, is uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research